E0501 - HIV Infection in African American Patients With HBV Seen in an Urban Medical Center

Jing Wang, MD¹, Anirudh R. Damughatla, DO¹, Mohamad Khaled Almujarkesh, MD¹, Astha Saini, DO¹, Paul Naylor, PhD², Murray N. Ehrinpreis, MD³, Milton G. Mutchnick, MD^2
1Wayne State University/Detroit Medical Center, Detroit, MI; ²Wayne State University School of Medicine, Detroit, MI; ³Wayne State University School of Medicine, Huntington Woods, MI

Introduction: Hepatitis B virus (HBV) is understudied in the African American (AA) population, a population that has a greater incidence of co-infection with HIV. The objective of this study was to evaluate the differences in pretreatment status and treatment response to HBV anti-viral medications in AA patients with mono-HBV and AA patients with HIV-HBV co-infection.

Methods: Patients with HBV DNA measurement(s) and a minimum of two visits to the university practice clinic before 2021 were identified (n=229). Most of these patients (115) were not on treatment at their earliest visit. The population consisted of 70% AA, 22% Asian/Middle East, and 8% Caucasian individuals. In our study, HIV-HBV patients were on average younger than the mono-HBV patients at first visit (42 vs. 51 years p< 0.0005) and were predominately AA males (98%). In contrast to mono-HBV patients, none of the HIV-HBV patients were Asian. Three groups of AA patients were defined: 1) Mono-HBV not on treatment, 2) Mono-HBV on treatment, and 3) HBV-HIV co-infected on treatment with HBV-specific anti-virals. Statistical analysis was done utilizing t-tests (ANOVA and paired) for continuous variables and mosaic plots with Pearson chi-square analysis for character variables.



Results: In the untreated AA population, 98% (43/44) of HIV-HBV patients had high HBV DNA ( >2000 IU/ml) in contrast to 51% (33/64) of mono-HBV patients. Mono-HBV patients who were subsequently treated had high HBV DNA (100%) and were more likely to be HBeAg positive (13/28=54%) as compared to patients who were not treated and were HBeAg negative (39/40=97%). Less than half of HIV-HBV patients were HBeAg positive (35/55=45%), and all were treated. The treatment response is shown in Table 1. HBV DNA was more likely to decrease in Mono-HBV patients than HIV-HBV patients (30% vs. 12%). As measured by APRI, fibrosis declined significantly with treatment compared to FIB-4, which did not.

Discussion: In our clinic population, AA HBV patients were more likely to be co-infected with HIV than non-AA patients. Mono-treatment patients were more likely to be treated if they were HBeAg positive and had high HBV DNA than HIV-HBV patients who were more likely to have seroconverted to HBeAg negative. HIV-HBV patients were less likely than mono-HBV patients to have a decline in high HBV viral load but were similar with respect to a reduction in fibrosis as defined by APRI.


Disclosures:


Jing Wang, MD¹, Anirudh R. Damughatla, DO¹, Mohamad Khaled Almujarkesh, MD¹, Astha Saini, DO¹, Paul Naylor, PhD², Murray N. Ehrinpreis, MD³, Milton G. Mutchnick, MD². E0501 - HIV Infection in African American Patients With HBV Seen in an Urban Medical Center, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.